Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The Potential Beneficial Effects of Resveratrol on Cardiovascular Complications in Marfan Syndrome Patients⁻Insights from Rodent-Based Animal Studies.

van Andel MM, Groenink M, Zwinderman AH, Mulder BJM, de Waard V.

Int J Mol Sci. 2019 Mar 5;20(5). pii: E1122. doi: 10.3390/ijms20051122. Review.

2.

Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.

Hibender S, Franken R, van Roomen C, Ter Braake A, van der Made I, Schermer EE, Gunst Q, van den Hoff MJ, Lutgens E, Pinto YM, Groenink M, Zwinderman AH, Mulder BJ, de Vries CJ, de Waard V.

Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1618-26. doi: 10.1161/ATVBAHA.116.307841. Epub 2016 Jun 9. Erratum in: Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):e81.

3.

Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.

De Backer J.

Verh K Acad Geneeskd Belg. 2009;71(6):335-71. Review.

PMID:
20232788
4.

Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm.

Jiménez-Altayó F, Meirelles T, Crosas-Molist E, Sorolla MA, Del Blanco DG, López-Luque J, Mas-Stachurska A, Siegert AM, Bonorino F, Barberà L, García C, Condom E, Sitges M, Rodríguez-Pascual F, Laurindo F, Schröder K, Ros J, Fabregat I, Egea G.

Free Radic Biol Med. 2018 Apr;118:44-58. doi: 10.1016/j.freeradbiomed.2018.02.023. Epub 2018 Feb 20.

PMID:
29471108
5.

Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.

Muiño-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, De Backer J.

Acta Cardiol. 2017 Dec;72(6):616-624. doi: 10.1080/00015385.2017.1314134. Epub 2017 Jun 28.

PMID:
28657492
6.

Aortopathy in Marfan syndrome: an update.

Romaniello F, Mazzaglia D, Pellegrino A, Grego S, Fiorito R, Ferlosio A, Chiariello L, Orlandi A.

Cardiovasc Pathol. 2014 Sep-Oct;23(5):261-6. doi: 10.1016/j.carpath.2014.04.007. Epub 2014 May 6. Review.

PMID:
24925629
7.

Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm.

Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, Vallely MP, Wilson MK, Keech AC, Jeremy RW.

J Am Coll Cardiol. 2016 Feb 16;67(6):618-626. doi: 10.1016/j.jacc.2015.11.039.

8.

Elevated expression levels of lysyl oxidases protect against aortic aneurysm progression in Marfan syndrome.

Busnadiego O, Gorbenko Del Blanco D, González-Santamaría J, Habashi JP, Calderon JF, Sandoval P, Bedja D, Guinea-Viniegra J, Lopez-Cabrera M, Rosell-Garcia T, Snabel JM, Hanemaaijer R, Forteza A, Dietz HC, Egea G, Rodriguez-Pascual F.

J Mol Cell Cardiol. 2015 Aug;85:48-57. doi: 10.1016/j.yjmcc.2015.05.008. Epub 2015 May 16.

9.

Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy?

Grewal N, Franken R, Mulder BJ, Goumans MJ, Lindeman JH, Jongbloed MR, DeRuiter MC, Klautz RJ, Bogers AJ, Poelmann RE, Groot AC.

Heart Vessels. 2016 May;31(5):795-806. doi: 10.1007/s00380-015-0703-z. Epub 2015 Jul 1.

10.

MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome.

Xiong W, Meisinger T, Knispel R, Worth JM, Baxter BT.

Circ Res. 2012 Jun 8;110(12):e92-e101. doi: 10.1161/CIRCRESAHA.112.268268. Epub 2012 May 1.

11.

Pathogenesis of aortic wall complications in Marfan syndrome.

Grewal N, Gittenberger-de Groot AC.

Cardiovasc Pathol. 2018 Mar - Apr;33:62-69. doi: 10.1016/j.carpath.2018.01.005. Epub 2018 Feb 2.

12.

Cardiovascular Management of Adults with Marfan Syndrome.

Isekame Y, Gati S, Aragon-Martin JA, Bastiaenen R, Kondapally Seshasai SR, Child A.

Eur Cardiol. 2016 Dec;11(2):102-110. doi: 10.15420/ecr/2016:19:2. Review.

13.

Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.

Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M; COMPARE study group.

Trials. 2010 Jan 12;11:3. doi: 10.1186/1745-6215-11-3.

14.

Ventricular-Vascular Coupling in Marfan and Non-Marfan Aortopathies.

Loeper F, Oosterhof J, van den Dorpel M, van der Linde D, Lu Y, Robertson E, Hambly B, Jeremy R.

J Am Heart Assoc. 2016 Nov 16;5(11). pii: e003705.

15.

Premature aortic smooth muscle cell differentiation contributes to matrix dysregulation in Marfan Syndrome.

Dale M, Fitzgerald MP, Liu Z, Meisinger T, Karpisek A, Purcell LN, Carson JS, Harding P, Lang H, Koutakis P, Suh M, Batra R, Mietus CJ, Casale G, Pipinos I, Baxter BT, Xiong W.

PLoS One. 2017 Oct 17;12(10):e0186603. doi: 10.1371/journal.pone.0186603. eCollection 2017. Erratum in: PLoS One. 2018 Jul 16;13(7):e0200985.

16.

Aortopathy in a Mouse Model of Marfan Syndrome Is Not Mediated by Altered Transforming Growth Factor β Signaling.

Wei H, Hu JH, Angelov SN, Fox K, Yan J, Enstrom R, Smith A, Dichek DA.

J Am Heart Assoc. 2017 Jan 24;6(1). pii: e004968. doi: 10.1161/JAHA.116.004968.

17.

Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome.

Hartog AW, Franken R, Zwinderman AH, Groenink M, Mulder BJ.

Expert Opin Pharmacother. 2012 Apr;13(5):647-62. doi: 10.1517/14656566.2012.665446. Epub 2012 Mar 7. Review. Erratum in: Expert Opin Pharmacother. 2012 Jul;13(10):1543.

PMID:
22397493
18.

Differences in Cardiovascular Manifestation of Marfan Syndrome Between Children and Adults.

Wozniak-Mielczarek L, Sabiniewicz R, Drezek-Nojowicz M, Nowak R, Gilis-Malinowska N, Mielczarek M, Łabuc A, Waldoch A, Wierzba J.

Pediatr Cardiol. 2019 Feb;40(2):393-403. doi: 10.1007/s00246-018-2025-2. Epub 2018 Nov 11.

19.

Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome.

Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT.

J Vasc Surg. 2008 Jan;47(1):166-72; discussion 172. doi: 10.1016/j.jvs.2007.09.016.

20.

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Viganò M, Odero A, Amato S, Tavazzi L, Arbustini E.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):354-62. doi: 10.2459/JCM.0b013e3283232a45.

PMID:
19430350

Supplemental Content

Support Center